NCT02721264 is a NA clinical trial of Fecal Microbiota Transplant in Non Alcoholic Steatohepatitis, sponsored by Institute of Liver and Biliary Sciences, India.

Who is sponsoring NCT02721264?

NCT02721264 is sponsored by Institute of Liver and Biliary Sciences, India.

What drugs are being tested in NCT02721264?

Interventions in NCT02721264: Fecal Microbiota Transplant, Standard Medical Treatment.

What condition does NCT02721264 study?

NCT02721264 studies Non Alcoholic Steatohepatitis.

Is NCT02721264 still recruiting?

NCT02721264 is currently status unknown. Last updated 15 February 2018.

Last reviewed 2018-02-15 · How we verify

NCT02721264

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.

Status unknown NA Last updated 15 February 2018

What this trial tests

NA trial testing Fecal Microbiota Transplant in Non Alcoholic Steatohepatitis in 112 participants. Status unknown.

Timeline

1 March 2016

Primary endpoint
30 June 2018

30 June 2018

Quick facts

Lead sponsor	Institute of Liver and Biliary Sciences, India
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	112
Start date	1 March 2016
Primary completion	30 June 2018
Estimated completion	30 June 2018
Sites	1 location across India

Drugs / interventions tested

Fecal Microbiota Transplant — full drug profile →
Standard Medical Treatment — full drug profile →

Conditions studied

Non Alcoholic Steatohepatitis — all drugs for Non Alcoholic Steatohepatitis →

Sponsor

Institute of Liver and Biliary Sciences, India

Who can join

Adults 18 to 75, any sex, with Non Alcoholic Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients of NASH (Non Alcoholic Steatohepatitis) cirrhosis with current or prior histological evidence of steatosis or steatohepatitis admitted under the Department of Hepatology at Institute of Liver and Biliary Sciences, who meet the inclusion criteria and who provide informed consent will be included in the study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.
Chen J, Vitetta L. · · 2020 · cited 235× · PMID 32717871 · DOI 10.3390/ijms21155214
Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H, Lin A, Kong M, Yao X, et al · · 2020 · cited 142× · PMID 31845054 · DOI 10.1007/s00535-019-01649-8
Fecal microbiota transplantation beyond Clostridioides difficile infections.
Wortelboer K, Nieuwdorp M, Herrema H. · · 2019 · cited 111× · PMID 31201141 · DOI 10.1016/j.ebiom.2019.05.066
Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma.
Peiseler M, Tacke F. · · 2021 · cited 53× · PMID 33578800 · DOI 10.3390/cancers13040730
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.
Hou S, Yu J, Li Y, Zhao D, et al · · 2025 · cited 34× · PMID 40013938 · DOI 10.1002/advs.202413197
Fecal Microbiota Transplantation in NAFLD Treatment.
Abenavoli L, Maurizi V, Rinninella E, Tack J, et al · · 2022 · cited 31× · PMID 36363516 · DOI 10.3390/medicina58111559
Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease.
Zhou J, Tripathi M, Sinha RA, Singh BK, et al · · 2021 · cited 28× · PMID 33490737 · DOI 10.20517/2394-5079.2020.134
Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease.
Philips CA, Augustine P, Yerol PK, Ramesh GN, et al · · 2020 · cited 27× · PMID 32274349 · DOI 10.14218/jcth.2019.00035

Verify or expand the search:

Other trials of Fecal Microbiota Transplant

Trials testing the same drug.

NCT05967871 — Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth · Phase 1 · recruiting
NCT05229289 — Efficacy and Safety of Fecal Microbiota Transplant for Secondary Prophylaxis of Hepatic Encephalopathy · NA · unknown
NCT04139577 — FMT In High-Risk Acute GVHD After ALLO HCT · Phase 1 · completed
NCT03363022 — To Assess the Role of Fecal Microbiota Transplant in Acute Liver Failure · NA · withdrawn
NCT03998423 — Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease · Phase 1 · terminated

Other recruiting trials for Non Alcoholic Steatohepatitis

Currently open trials in the same condition.

NCT06676813 — Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis. · NA · recruiting
NCT05463796 — InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer · recruiting
NCT05821010 — Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis · Phase 2 · recruiting
NCT05574036 — Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia · Phase 2 · active not recruiting

Other Institute of Liver and Biliary Sciences, India trials

Trials by the same sponsor.

NCT07480005 — To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies · recruiting
NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07465471 — Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. · NA · not yet recruiting
NCT07433881 — Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis · not yet recruiting
NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02721264 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Liver and Biliary Sciences, India
Last refreshed: 15 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02721264.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing